Anti-CXCL5 therapy ameliorates IL-17-induced arthritis by decreasing joint vascularization - sprookjes - yvandenbroek - TriplyDB

Anti-CXCL5 therapy ameliorates IL-17-induced arthritis by decreasing joint vascularization

Anti-CXCL5 therapy ameliorates IL-17-induced arthritis by decreasing joint vascularization

http://www.wikidata.org/entity/Q34802798

about

Solution Structure of CXCL5 — A Novel Chemokine and Adipokine Implicated in Inflammation and Obesity Ligation of TLR5 promotes myeloid cell infiltration and differentiation into mature osteoclasts in rheumatoid arthritis and experimental arthritis.CXCL5 drives neutrophil recruitment in TH17-mediated GN Interleukin-17A and Neutrophils in a Murine Model of Bird-Related Hypersensitivity Pneumonitis.An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis.Role of the CCL21 and CCR7 pathways in rheumatoid arthritis angiogenesis.TLR2 deletion promotes arthritis through reduction of IL-10 Role of TH-17 cells in rheumatic and other autoimmune diseases The pathogenic role of angiogenesis in rheumatoid arthritis.Angiogenesis in rheumatoid arthritis is fostered directly by toll-like receptor 5 ligation and indirectly through interleukin-17 induction.Extracellular Vesicles and Autophagy in Osteoarthritis.Pathways for bone loss in inflammatory disease.Epidermal growth factor receptor (EGFR) as a therapeutic target in rheumatoid arthritis.Therapeutic potential of interleukin-17 in inflammation and autoimmune diseases.Molecular Basis of Chemokine CXCL5-Glycosaminoglycan Interactions Focal bone involvement in inflammatory arthritis: the role of IL17.Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis.Identification of a Novel Toll-like Receptor 7 Endogenous Ligand in Rheumatoid Arthritis Synovial Fluid That Can Provoke Arthritic Joint Inflammation.Genome-wide expression differences in anti-Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea.Fas signaling in macrophages promotes chronicity in K/BxN serum-induced arthritis.

P2860

Q27682811-A8232BAD-4D6B-4A5F-8124-F90F61DAF737 Q34289171-E2C8984B-08C5-4DFF-BCDD-E82DF2802BAB Q34787760-2863FDE7-304A-4A53-900A-DA0D545EDBCC Q35772669-41C1EB54-856C-44C9-AC5D-DF9477C185BE Q35996543-98506E49-40AC-480F-AD4E-E5CDF946E5B4 Q36131157-5AE053A8-67AD-47A9-B004-F3919F6F5C90 Q36775416-EDC4B8BC-DF9F-45BA-8C5A-C887A64320FE Q36795816-D5FAC21B-B2DE-465E-AB65-16505CEA61B9 Q36934777-05C24B3D-4F99-4D31-BABE-13A55DE58423 Q37060590-8C592804-FC5C-4707-AFA7-FEED3EAA834D Q37547584-D00B6F37-C753-4644-AC74-5C80D3A08550 Q38004935-99D21DF3-B0F4-4140-AD58-FA685D8BC91E Q38062331-ED624611-CEDF-4167-A6CA-97C5F66E6C60 Q38154628-8B1C527C-6BA1-4AEB-B9F0-7402011E69E9 Q38291506-FE30834E-1C8F-4E12-8C51-74EE0CC95DBF Q38295616-D2B11E69-82BA-4AE0-B14D-DDE3051AC840 Q39321350-0FADFA44-6BCB-48B9-AD98-8A7804FFFFE6 Q40154356-CA386E9F-0AB4-4785-B573-FD7851B0123D Q41018514-AEA5F236-B561-4A2D-B272-EF911DEA46D3 Q41423380-E67EDD86-3DA9-46EF-8892-BB3C77E3F0FA Q41822725-68CF4E7A-D54C-4353-9811-9EC902AEDF3D

P2860

Anti-CXCL5 therapy ameliorates IL-17-induced arthritis by decreasing joint vascularization

http://www.wikidata.org/entity/Q34802798

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Anti-CXCL5 therapy ameliorates ...... creasing joint vascularization

@ast

Anti-CXCL5 therapy ameliorates ...... creasing joint vascularization

@en

Anti-CXCL5 therapy ameliorates ...... creasing joint vascularization

@nl

type

label

Anti-CXCL5 therapy ameliorates ...... creasing joint vascularization

@ast

Anti-CXCL5 therapy ameliorates ...... creasing joint vascularization

@en

Anti-CXCL5 therapy ameliorates ...... creasing joint vascularization

@nl

prefLabel

Anti-CXCL5 therapy ameliorates ...... creasing joint vascularization

@ast

Anti-CXCL5 therapy ameliorates ...... creasing joint vascularization

@en

Anti-CXCL5 therapy ameliorates ...... creasing joint vascularization

@nl

P1433

Q34802798-34678121-8AF3-4072-9575-52ACB447C528

P1476

Q34802798-32ACCD09-00B5-48BA-A67C-05378E0F2E85

P2093

Q34802798-03731A8D-F107-4348-B7AC-0FC56EC25D2E

Q34802798-329D4732-F933-4F6A-AE7F-C3BE9F97EDA0

Q34802798-45409420-3F1E-42C7-A622-0F42274390F3

Q34802798-797BD1FE-8D44-40FD-85FF-4190FC15BCCF

Q34802798-8A76F24C-6DD1-4478-BA4B-B4723585AFDF

Q34802798-F2FD2057-F56F-4532-8D0F-373D5B68263F

Q34802798-FB5CBEF9-90F2-4C48-B084-C504AE538C53

P2860

Q34802798-03197B47-428A-4DEF-9A7D-E293999881FD

Q34802798-076CB4C0-84D3-4944-BD67-8480E62DF0D4

Q34802798-07D38ED5-F458-4C66-AD3C-2FDD6AAECCB2

Q34802798-17BB6961-74D5-43A4-8659-FBF180B91A6A

Q34802798-180EC31B-C0EA-4BFA-9731-15BDCCCCEBCE

Q34802798-1D673D75-B09E-4982-8A2F-52C9CCCE6910

Q34802798-24EE8191-447D-41DC-8B2A-63767A8577D6

Q34802798-34CF88D4-9B60-45F2-9BE6-FC0E5E216098

Q34802798-454F57D4-94B8-405A-860B-C1674BF1F820

Q34802798-48CE4A9C-DFAC-4EF3-9FFE-5CF0AFD1D586

P2888

Q34802798-40FE780F-07DE-4C65-933A-D672FAE377A7

P304

Q34802798-FBCFBD8C-6379-4A7F-BD23-266399FF6BA4

P31

Q34802798-3CC38F37-9662-4B09-8FC1-D46B2F346564

P356

Q34802798-24CB7051-A783-4FD6-A6EE-690023E0C6D5

P433

Q34802798-51ADE913-0725-4360-9234-51FA87C35282

P478

Q34802798-BD078929-7C75-42A1-8FC5-9FC1DEDADC47

P50

Q34802798-B181667F-D6F0-4849-A479-F862624CC22E

P577

Q34802798-96E3E82D-65A2-40F6-96B0-2493E08CFFA7

P698

Q34802798-B0817C89-0C75-4A8F-8195-75DF97BDACA6

P932

Q34802798-561D991F-AF03-4256-8759-178804B7D144

P356

S10456-011-9227-Z

P1433

P1476

Anti-CXCL5 therapy ameliorates ...... creasing joint vascularization

@en

P2093

Arthur M Mandelin

http://www.w3.org/2001/XMLSchema#string

Jay K Kolls

http://www.w3.org/2001/XMLSchema#string

Mark Gonzalez

http://www.w3.org/2001/XMLSchema#string

Michael V Volin

http://www.w3.org/2001/XMLSchema#string

Nathan D Chamberlain

http://www.w3.org/2001/XMLSchema#string

Sarah R Pickens

http://www.w3.org/2001/XMLSchema#string

Shiva Shahrara

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence of IL-18 as a novel angiogenic mediator

Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis

Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis

Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Cell surface heparan sulfate participates in CXCL1-induced signaling

Chemokine-cytokine cross-talk. The ELR+ CXC chemokine LIX (CXCL5) amplifies a proinflammatory cytokine response via a phosphatidylinositol 3-kinase-NF-kappa B pathway

GRO family chemokines are specialized for monocyte arrest from flow

Evolving concepts of rheumatoid arthritis

Increased granulopoiesis through interleukin-17 and granulocyte colony-stimulating factor in leukocyte adhesion molecule-deficient mice.

P2888

s10456-011-9227-z

P304

443-455

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10456-011-9227-Z

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Richard M. Pope

P577

2011-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21779896

http://www.w3.org/2001/XMLSchema#string

P932

4281892

http://www.w3.org/2001/XMLSchema#string